News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Novartis Pharmaceuticals Corporation Drug Works For Parkinson’s Says FDA Staffer
May 16, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
An Alzheimer's drug made by Novartis Pharmaceuticals effectively treats dementia in patients with Parkinson's disease, but it is unclear if such mental impairments are two distinct conditions, U.S. Food and Drug Administration staff said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Novartis
MORE ON THIS TOPIC
Rare diseases
BridgeBio touts kidney benefits for Attruby, differentiating from amyloidosis competitors
July 6, 2026
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes
July 2, 2026
·
2 min read
·
Tristan Manalac
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie